Références


  • Exbrayat-C. Col de l’utérus. Évolution de l’incidence et de la mortalité par cancer en France de 1978 à 2000. Institut National de Veille Sanitaire; 2003. p. 107-112.
    Disponible sur le site http://www.invs.sante.fr/

  • Walboomers-JMM et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. Journal of Pathology 1999; 189(1):12-19.

  • Mclntosh-N. Human papillomavirus and cervical cancer. Strategy papers, paper 8, may 2000. JHPIEGO Corporation 2000.
    Disponible sur le site http://www.jhpiego.org/

  • Baseman-JG; Koutsky-LA. The epidemiology of human papillomavirus infections. Journal of Clinical Virology 2005; 32S(Suppl 1):S16-24.

  • Bosch-FX et al. The causal relation between human papillomavirus and cervical cancer. Journal of Clinical Pathology 2002; 55(4):244-265

  • Koutsky-L. Epidemiology of genital Human Papillomavirus infection. American Journal of Medecine 1997; 102 (5A): 3-8

  • Moscicki-AB. Impact of HPV infection in adolescent populations. Journal of Adolescent Health. 2005; 37:S3-9

  • Duport-N. Données épidémiologiques sur le cancer du col de l’utérus. État des connaissances. Institut National de Veille Sanitaire; 2007.
    Disponible sur le site: http://www.invs.sante.fr

  • Munoz-N; Bosh-FX; Castellsague-X et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. International Journal of Cancer 2004; 111: 278-285

  • Schiffman-M et al. Human papillomavirus and cervical cancer. Lancet 2007; 370:890-907.

  • Résumé des caractéristiques du produit. Cervarix®. GlaxoSmithKline, 2007

  • Parkin-DM; Bray-F; Ferlay-J; Pisani-P. Global Cancer Statistics, 2002. A Cancer Journal for Clinicians 2005; 55:74-108.

  • Harper-DM et al. Sustained efficacy up to 4-5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a Randomised Control Trial. The Lancet 2006; 367(9518): 1247-1255.

  • Dossier AMM Cervarix® - Étude HPV 007-2007

  • Bergeron-C; Cohet-C; Bouée-S; Lorans-C; Rémy-V. Management of abnormal smears intraepithelial neoplasia and associated treatment costs in France ; Coût de la prise en charge des frottis anormaux et des néoplasies intraépithéliales du col de l'utérus en France. Bulletin Epidémiologique Hebdomadaire 2007; (1):4-6.

  • Franco-EL, Harper-DM. Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine 2005; 23(17-18):2388-2394.

  • Burd-EM. Human papillomavirus and cervical cancer. Clinical Microbiology Reviews 2003; 16(1): 1-17.

  • Harper-DM et al. Efficacy of a bivalent L1 virus-like particle in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364(9447): 1757-1765.

  • Goldie-SJ et al. Projected clinical benefits and cost-effectiveness of a HPV 16/18 vaccine. Journal of the National Cancer Institute 2004; 96(8): 604-615.

  • Basen-Engquist-K et al. Cervical cancer behavorial factors related to screening, diagnosis, and survivors quality of life. Cancer 2003; 98(9, Suppl): 2009-2014

  • Rogstad-KE. The psychological impact of abnormal cytology and colposcopy. British Journal of Obstetrics and Gynaecology 2002; 109:364-368.

  • De-Jong-A et al. Human Papillomavirus Type 16-Positive Cervical Cancer Is Associated with Impaired CD4+ T-Cell Immunity against Early Antigens E2 and E6. Cancer Research 2004; 64:5449-5455

  • Conway-K. Attitudes to Papanicolaou smears. Journal of Psychosomatic Obstetrics and Gynaecology 1996; 17(4):189-194

  • Baseman-JG; Koutsky-LA. The epidemiology of human papillomavirus infections. Journal of Clinical Virology 2005; 32S(Suppl 1):S16-24.

Accueil > Références